Rosiglitazone and pulmonary oedema: An acute dose-dependent effect on human endothelial cell permeability

Diabetologia

Volumn 46, Issue 2, 2003, Pages 288-290

  Idris, I ^b   Gray, S ^b   Donnelly, R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NONE

Author keywords

Endothelial function; Heart failure; Oedema; Permeability; Pulmonary; Rosiglitazone; Thiazolidinedione

Indexed keywords

ALBUMIN; BIOMATERIAL; COLLAGEN; EVANS BLUE; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE;

ARTICLE; BLOOD VESSEL TONE; CELL MEMBRANE PERMEABILITY; CLINICAL PRACTICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG WITHDRAWAL; ELECTRIC RESISTANCE; ENDOTHELIUM CELL; FLUID RETENTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INCUBATION TIME; KIDNEY CLEARANCE; LUNG ALVEOLUS CELL; LUNG EDEMA; LUNG ENDOTHELIUM; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY ARTERY;

EID: 0037301051     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-002-1008-1     Document Type: Article

References (10)

1. Gorson DM (1999) Significant weight gain with Rezulin therapy. Arch Intern Med 159:99
2. Hirsch IB, Kelly J, Cooper S (1999) Pulmonary edema associated with troglitazone therapy. Arch Intern Med 159:1811
3. Thomas ML, Lloyd SJ (2001) Pulmonary edema associated with rosiglitazone and troglitazone. Ann Pharmacother 35:123-124
4. Hilsted J, Christensen NJ (1992) Dual effect of insulin on plasma volume and transcapillary albumin transport. Diabetologia 35:99-103
5. Hippenstiel S, Krull M, Ikemann A, Risau W, Clauss M, Suttorp N (1998). VEGF induces hyperpermeability by a direct action on endothelial cells. Am J Physiol 274:L678-L684
6. Idris I,Tyreman N, Gray S, Donnelly R (2002) Losartan attenuates hyperpermeability responses to glucose and VPF but not Angiotensin II. Diabetologia 45:291-292
7. Walker AB, Chattington PD, Buckingham RE, Williams G (1999). The thiazolidinedione rosiglitazone (BRL49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48:1448-1453
8. Bishop-Bailey D, Hla T (1999) Endothelial cell apoptosis induced by the peroxisome proliferators-activated receptor (PPAR) ligand 15-deoxy-δ12,14-prostaglandin J2. J Biol Chem 274:17042-17048
9. Yamakawa K, Hosoi M, Koyama H et al. (2000). Peroxisome proliferator-activated receptor-γ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun. 271:571-574
10. Hinder F, Booke M, Traber LD, Traber DL (1997) Nitric oxide and endothelial permeability. J Appl Physiol 83:1941-1946